series-a
Stage
2
Investors
About
Araris Biotech develops proprietary peptide linker technology for antibody-drug conjugates (ADCs) that enables the stable, site-specific, and highly soluble attachment of potent anti-cancer drugs to antibodies, improving ADC efficacy and safety in targeted cancer therapies.
Explore Araris Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.